Although new molecular-targeted drugs, including FLT 3 inhibitors, IDH 1 inhibitors, IDH 2 inhibitors, and Bcl-2 inhibitors, have brought a new dawn to the treatment of AML patients [3, 4] as research on the molecular biology of diseases deepens, these patient’s prognosis is still poor. The gene discussed is BCL2; the disease is acute myeloid leukemia.